Skip to main content
Clinical Trials/CTRI/2023/10/058546
CTRI/2023/10/058546
Not yet recruiting
Phase 2

Comparison of outcome in Terlipressin and ultra-low dose Terlipressin plus noradrenalin infusion in HRS-AKI patients of ACLF - NI

on sponsered0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: K77- Liver disorders in diseases classified elsewhere
Sponsor
on sponsered
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
on sponsered

Eligibility Criteria

Inclusion Criteria

  • ACLF as per APASL criteria
  • AKI at admission as defined by ICA\-AKI criteria
  • HRS\-AKI grade II \& grade III as defined by ICA 12 hour of admission

Exclusion Criteria

  • Age \<18 years \>70 years
  • Septic shock
  • Patient with HCC outside Milan’s criteria
  • Severe Hyponatremia (Na \<120 MEq/L)
  • Patients with RH failure, CAD, PVD, arrhythmias and cardiomyopathy
  • Pregnancy or Lactating mother
  • Grade III/IV HE or Shock requiring inotropes or patients on mechanical ventilator at time of randomization
  • In\-hospital new AKI
  • Active urinary sediments – 2\+ albumin or above, dysmorphic RBCs
  • Known CKD, obstructive uropathy

Outcomes

Primary Outcomes

Not specified

Similar Trials